Browsing Tag
Citius Pharmaceuticals
5 posts
What the LYMPHIR–pembrolizumab combination signals for the future of immunotherapy resistance (NASDAQ: CTOR)
Citius Oncology reports LYMPHIR immunotherapy data in gynecologic cancers. Discover what the trial signals for the future of cancer immunotherapy.
Citius Oncology bets on AI-powered sales strategy to fast-track LYMPHIR cancer drug launch
Citius Oncology launches an AI-powered platform to boost LYMPHIR’s commercial debut in CTCL, reshaping oncology sales strategies with precision targeting.
Dr. Reddy’s Labs signs deal worth up to $150m to sell E7777 rights to Citius
Dr. Reddy’s Laboratories (Dr. Reddy’s Labs) has agreed to divest its rights to E7777, an engineered IL-2-diphtheria toxin…
Citius seeks FDA nod for evaluating stem cell therapy for ARDS in COVID-19
Citius Pharmaceuticals has made a Pre-IND submission to the US Food and Drug Administration for a novel stem…
Citius Pharmaceuticals expands scientific advisory board to enhance focus on infectious disease treatments
Citius Pharmaceuticals, a specialty pharmaceutical company based in New Jersey, has announced the addition of Dr. Lawrence Mermel…